CT-388's compound patents run to approximately 2040-2041 (US), creating a five-year exclusivity window as the sole branded dual GLP-1R/GIPR agonist after tirzepatide faces generic entry
Practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases
An extensive revision of the actions of fibroblasts on different conditions uncovers the existence of numerous diseases in which this cell type plays a pathogenic role, either due to an exacerbation of their 'structural' side, or a dysregulation of their 'immune side'
They work well for some people and unlike the narrative that really is getting pushed right now that they are lifelong, they do not have to be
External resources STEP 1 Trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (NEJM) STEP 5 Trial: Two-Year Effects of Semaglutide (Nature Medicine) Semaglutide Effects on Nutritional Metrics Including B12 (PMC) Semaglutide for Overweight and Obesity: A Comprehensive Review (PMC) For researchers serious about optimizing their semaglutide B12 protocol, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, dosing calculators, and a community of thousands who have navigated these exact questions
.png)
